CD155-CD96 keeps quiescent persister tumor cells in check

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Colorectal cancer treatment often involves neoadjuvant chemotherapy.
• Chemotherapy can lead to the survival of resistant tumor cell populations.
• Understanding the mechanisms of treatment resistance is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the characteristics of quiescent persister tumor cells (PTCs) after neoadjuvant chemotherapy in colorectal cancer.
• To determine the interaction between PTCs and tumor-infiltrating immune cells.
• To identify potential therapeutic strategies to overcome treatment resistance.

Main Methods:

• Analysis of colorectal cancer patient samples treated with neoadjuvant chemotherapy.
• Flow cytometry to identify and quantify specific cell populations (PTCs, CD8+ T cells).
• Assessment of cell surface marker expression (CD155, CD96).
• Functional assays to evaluate T cell activity and anti-tumor responses.

Main Results:

• Quiescent persister tumor cells (PTCs) are enriched following neoadjuvant chemotherapy.
• PTCs exhibit increased expression of CD155, a cell adhesion molecule.
• CD155 on PTCs interacts with CD96 on CD8+ T cells, leading to T cell dysfunction.
• Targeted therapy against CD96 restored anti-tumor activity of T cells.

Conclusions:

• Neoadjuvant chemotherapy enriches colorectal cancer PTCs that express CD155.
• CD155-CD96 interactions impair anti-tumor CD8+ T cell immunity.
• CD96-targeted monoclonal antibody therapy shows promise for restoring anti-tumor activity in resistant colorectal cancer.